Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21054378 | 0.82 | CA12 (0.40) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL20269597 | 0.81 | GAA (0.49) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL1971697 | 0.81 | MAPT (0.44) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL31073370 | 0.80 | GRM6 (0.35) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13748344 | 0.80 | SMN1; SMN2 (0.49) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL20269630 | 0.79 | ABL1 (0.42) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL27191784 | 0.79 | GAA (0.55) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL1973369 | 0.78 | ALDH1A1 (0.40) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL365155 | 0.78 | DAO (0.42) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27390129 | 0.78 | SMN1; SMN2 (0.40) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109140-A1 | 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2024255765-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-20240376091-A1 | THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-112480116-B | PKB inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024051717-A1 | COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023133229-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133229-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023004897-A1 | THIADIAZOLE AMIDE COMPOUND AND USE THEREOF | 浙江大学 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023004897-A1 | THIADIAZOLE AMIDE COMPOUND AND USE THEREOF | 浙江大学 | 2023-02-02 | — | — | WO | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | MAPT 3584/4885CA12 4808/4885CA1 4681/4885 |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | MAPT 758/4885CA12 4503/4885CA1 3992/4885 |
| US-20250109140-A1 | 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SNRPA, HNRNPA3, HNRNPUL1 | MAPT 2710/4885CA12 4878/4885CA1 4883/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | MAPT 1370/4885CA12 4742/4885CA1 4584/4885 |
| US-20240376091-A1 | THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS | AR, GPER1, CYP19A1 | MAPT 2339/4885CA12 4032/4885CA1 4123/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | MAPT 2963/4885CA12 2086/4885CA1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.